The psychedelic therapy market is one of the most exciting emerging industries and is a vertical that we have been highly focused on. We expect 2021 to be a transformational year for the psychedelic sector as companies prepare to report Phase 3 clinical trial data.
We expect positive phase 3 clinical trial data to serve as a catalyst for the entire industry and are favorable on the potential impact that these studies could have. Today, we want to highlight a company that would benefit from this potential and believe our readers should be aware of this opportunity.
Numinus Wellness Inc. (TSXV: NUMI) has been highly focused on supporting the use of psychedelic-assisted psychotherapies (PAP) and is an opportunity that we have been closely following.
We believe that Numinus has an attractive operating structure and are favorable on the divisions that makeup the business. We are of the opinion that the company’s divisions can create value for each other and have highlighted them below:
- Numinus Health – delivers treatments through clinics and virtual services, with clinics in Vancouver and Montreal.
- Numinus R&D – develops clinical and therapeutic protocols to use in treatments, in collaboration with research partners and regulators.
- Numinus Bioscience – develops formulations and methods for a safe supply, using Health Canada licenses, scientific expertise and cutting-edge technology.
Last week, Numinus announced that it plans to significantly expand its psychedelics research laboratory by late 2021 and we believe that this could prove to be an important growth catalyst. The company reported that a 7,500-square-foot expansion will be developed and housed in a building that is leased by Numinus and is adjacent to the current lab.
The expansion was reported shortly after Numinus received amendments to its federal license to allow for the possession, production, assembly, sale, export and/or delivery of a variety of psychedelics (i.e. Ketamine, LSD, Mescaline, DMT, MDMA, Psilocin, and Psilocybin). We are favorable on the track record of execution that is associated with Numinus and will monitor how the story evolves from here.
The investment in an expanded lab represents a key milestone for Numinus and provides the business with the necessary foundation to advance PAP in Canada and around the world. Once the expansion is completed, the facility will enhance the company’s intellectual property (IP) and partnerships strategy. The completion of the expansion is expected to be a major revenue generator through analytics testing for psychedelics and other contract services.
The current lab is conducting innovative work in areas such as Psilocybe mushroom cultivation and extraction, formulation studies and a genotypically verified spore bank and tissue culture library. The expanded state-of-the-art facility is also expected to increase Numinus’ supply of consistent and effective psychedelics for clinical use and trials that are being undertaken by academic, not-for-profit and for-profit entities.
The expanded facility is also expected to add several psychedelic substances and capabilities to contract lab services, increase capacity for high-throughput psychedelics testing, and enhance research and development activities in a wide array of psychedelics. We are bullish on the growth prospects that are associated with the expanded state-of-the-art facility and will monitor how the story advances from here.
An Execution Story to be Aware of
Last month, Numinus announced that its MDMA compassionate access trial achieved significant progress toward treating patients with post-traumatic stress disorder (PTSD). This trial is being pursued in collaboration with MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), the leading developer of the treatment protocols, research and MDMA-assisted therapy training programs.
During the last month, Numinus has come under pressure and has come well off its 2021 highs. We are favorable on the recent announcements from the company and believe that the market is discounting the growth prospects that are associated with these developments.
During the last quarter, Numinus has announced several important developments and we will continue to monitor the opportunity. If you are interested in learning more about Numinus, please send an email to email@example.com with the subject “Numinus” to be added to our distribution list.